Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications. [PDF]
Curr Obes RepLee J, You JH, Park HJ, Roh JL, Paek SH.
europepmc +1 more source
Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. [PDF]
J Cosmet DermatolArgobi Y +6 more
europepmc +1 more source
GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review. [PDF]
Int J Mol SciOrozco MP +2 more
europepmc +1 more source
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]
Front Endocrinol (Lausanne)Alhazmi A, le Roux CW.
europepmc +1 more source
Oral Treatment of Obesity by GLP-1 and Its Analogs. [PDF]
PharmaceuticsHoller N +4 more
europepmc +1 more source
GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]
Clin CardiolAhmed M +7 more
europepmc +1 more source
Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025). [PDF]
CureusMakkena HB.
europepmc +1 more source
Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease. [PDF]
Neurol GenetZangas P, Omarov M, Georgakis MK.
europepmc +1 more source
Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries. [PDF]
JBRA Assist ReprodPiazza MJ.
europepmc +1 more source
Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis. [PDF]
J Diabetes Metab DisordKamel-Abusalha L +6 more
europepmc +1 more source